Bio-Rad’s New StarBright Blue and Yellow Dyes Enhance Multiplex Flow Cytometry

Publication
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, March 2023
Volume 18
Issue 3

Bio-Rad’s newly launched StarBright Blue and StarBright Yellow dyes are intended for use in various flow cytometry applications.

Bio-Rad Laboratories introduced its new StarBright Blue and StarBright Yellow dyes in February 2023. The dyes are designed to promote flexibility in conventional and full spectrum flow cytometry applications. Dyes in the Starbright series are conjugated to flow validated antibodies, supporting flow cytometry panel design in immunology design.

The two new variations in the Starbright series are intended to expand research capabilities across blue (488 nanometers) and yellow (561 nanometers) lasers. According to a Feb. 13, 2023 press release, the new dyes offer exceptional brightness in conjunction with narrow excitation and emission profiles, allowing for precise resolution.

StarBright dyes are compatible with most experimental protocols and flow cytometers without the need for special buffers. Additionally, minimal lot-to-lot variation helps to ensure reproducible and consistent staining, and the dyes are resistant to photobleaching with no loss of signal in fixation, according to the release.

"The continued development of the Bio-Rad StarBright Dye portfolio, now totaling 28 dyes and spanning multiple lasers, gives researchers greater choice and flexibility across multiplex flow cytometry applications, offering superior alternatives to existing dyes," said Mike Blundell, product manager, Flow Cytometry, Life Science Group, Bio-Rad, in the release. "With the launch of the StarBright Blue and StarBright Yellow Dyes, Bio-Rad now has the most comprehensive series of new dyes specifically designed for flow cytometry."

Source: Bio-Rad

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content